Overview

The Effect of an Anti-obesity Drug, Semaglutide, As Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (dietician) with Regards to Change in Weight and Intracranial Pressure

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-30

Target enrollment:

Participant gender:

Summary

50 patients with verified new-onset Idiopathic Intracranial Hypertension are randomly allocated to standard weight management (dietician counselling) or trial intervention consisting of subcutaneous injections with Semaglutide for 10 months combined, in the initial 8 weeks following diagnosis, with a Very Low Calorie-Diet (max 800 kcal/day)

Phase:

PHASE4

Details

Lead Sponsor:

Rigmor Hjland Jensen

Collaborators:

Odense University Hospital
Rigshospitalet, Denmark
University of Copenhagen

Treatments:

semaglutide